We established a tumor prediction model by combining clinical factors (including molecular subtype and Ki67 status) and gene mutation information (MSH2, NOTCH4, PIK3CA, SETBP1, TP53, EGFR, FOXP1, IL7R, NFKB1), which had good sensitivity and specificity for predicting pCR in the training set, validation set, and external validation set. This evidence concerns the gene SETBP1 and neoplasm.